Navigation Links
MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
Date:2/3/2009

are services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit www.astrazeneca.com

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the collaboration between MAP Pharmaceuticals and AstraZeneca. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: regulatory review and approval of UDB; the conduct and timing of clinical trials; the availability, pricing and marketing of competitive products, including generic products; any inability to realize all of the anticipated benefits of the development and commercialization arrangement fully or on the anticipated timeline; a downturn in the pharmaceutical industry; unexpected variations in market growth and demand for pediatric asthma products; or the effect of political or economic instability internationally on the sales or production of UDB. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... have discovered a chemical alteration in a single human ... larger studies, could give doctors a simple blood test ... , The discovery, described online in The American ... gene involved in the function of the brain,s response ... what might otherwise be an unremarkable reaction to the ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... the author of this program claims that he cured his ... the author decided to share part of his experience. ... nasal polys permanently and naturally in just 4 days. Since ... share it with sufferers from all around the world. ...
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... holistic system that will permanently eliminate all the symptoms associated ... natural treatment will banish symptoms such as mild hearing loss, ... heard by patients will be gone forever. , The method ... The author of this program says that at the end ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... , ARLINGTON, Va., July 23 During ... Majority Leader Tom Daschle and Blue Dog Democrat Rep. Jason ... in the reform of the U.S. healthcare system. The ... medical equipment and services. The American Association for Homecare hosted ...
... , , , ... ), a leading provider of optical components, modules and subsystems, today announced ... June 27, 2009. Oclaro, Inc. was formed April 27, 2009 from ... Avanex Corporation. , , "Being positive Adjusted ...
... Calif., July 23 Oscar Wright, chief executive officer of United Advocates ... Donuts shop, participated in an interview and debate Wednesday on KTVU,s ... , Oscar Wright released this statement today: , ... the U.S. Small Business Administration, I appreciate an individual,s goal to live ...
... might be slowing down among poor families , THURSDAY, ... low-income families in the United States are considered obese, a ... that the news is not all bad: The childhood obesity ... this group. , Among 2- to 4-year-olds from low-income families, ...
... , , PITTSBURGH, July 23 ... stopping in Pennsylvania throughout the week of July 27-31 at ... access information on programs that provide prescription medicines for free ... 8.2 percent -- compared to 5.1% a year ago -- ...
... a cancer-killing protein, scientists at the University of Kentucky,s Markey ... UK professor of radiation medicine, have determined that the tumor-suppressor ... expressing the Par-4 gene, is in fact secreted by most ... cancer cells by binding to receptors on the cell surface. ...
Cached Medicine News:Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 2Health News:Sen. Tom Daschle, Rep. Jason Altmire, Healthcare Experts Tout Homecare as Cost-Effective Solution in the Healthcare Reform Process 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 2Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 3Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 4Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 5Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 6Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 7Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 8Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 9Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 10Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 11Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 12Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 13Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 14Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 15Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 16Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 17Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 18Health News:Oclaro Reports Positive Adjusted EBITDA in First Post-Merger Quarter 19Health News:Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 2Health News:1 in 7 Low-Income Preschoolers Is Obese 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 4Health News:Human cells secrete cancer-killing protein, UK study finds 2
(Date:7/29/2014)... , July 29, 2014 New technology in ... could allow physicians to see and assess brain tissue ... according to study authors who released their findings today ... Annual Meeting in Colorado Springs, CO. ... the field of neurointervention, a specialty that facilitates stroke ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Seen Since Presentation at ASCO ... Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, Calif., Sept. ... a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 inhibitor,demonstrated antitumor ...
... Sept. 7 Roche announced today that three,clinical data ... for presentation at the 2007 Breast Cancer Symposium in ... abstracts include data from the XeNA (Xeloda in NeoAdjuvant),trial, ... Herceptin in,patients with invasive breast cancer. The third presentation ...
Cached Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: